Editas Medicine, Inc. EDIT 深 沪

Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Development Candidate, EDIT-401, And Its Potential As A One-Time Treatment For Hyperlipidemia

The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Boston, including one oral presentation and two poster presentations, as well as one oral

05-14 18:09

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine shared promising preclinical data for EDIT-401, a potential one-time treatment for hyperlipidemia. In non-human primates, a single dose achieved ≥90% LDL-C reduction, with durability through ~6 months and a favorable safety profile. The data also suggest that dose adjustments may not be needed for HeFH patients. EDIT-401's targeting efficiency and safety support its advancement toward clinical development.

05-14 10:01

美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价

今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元

05-06 11:29

Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3.5 to $4.

05-06 04:51

Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of $(0.43) per share from

05-05 19:29

Editas Medicine Announces First Quarter 2026 Results and Business Updates

05-05 11:00

Editas Medicine To Present New Preclinical Data Demonstrating Progress Of EDIT-401 As Potential Treatment For Hyperlipidemia At Multiple Upcoming Conferences

Five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at

04-28 04:39

Editas Medicine Sees USPTO Reaffirm Broad Institute's CRISPR Patent Priority

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent

03-27 19:05

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed the Broad Institute's priority in CRISPR/Cas9 gene editing patents, marking the third favorable decision for Broad. This ruling reinforces Editas's confidence in their intellectual property, particularly for developing transformative in vivo gene editing therapies like EDIT-401, which has shown significant LDL cholesterol reduction in preclinical studies. The patents a...

03-27 11:00

Epstein tapped an elite network for stock, startup tips - WSJ

Jeffrey Epstein reportedly tapped his wide network of powerful contacts to gather insights on stocks, startups, and corporate deals as he blurred the line between networking and potentially sensitive ...

03-18 19:57